<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052948</url>
  </required_header>
  <id_info>
    <org_study_id>A7231031</org_study_id>
    <nct_id>NCT01052948</nct_id>
  </id_info>
  <brief_title>The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events</brief_title>
  <official_title>The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the association between cabergoline and other dopamine agonists (DAs), and
      symptomatic, diagnosed serious cardiopulmonary disorders, including:

        1. Cardiac valve regurgitation

        2. Diffuse Pleural/pulmonary thickening and pericardial and retroperitoneal fibrosis

        3. Heart failure

        4. Total, cardiac and respiratory mortality
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Fibrotic Valvular Heart Disease Per 10,000 Participant-Years of Follow-Up</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Occurrence of: mitral stenosis with insufficiency, other unspecified mitral valve diseases, mitral or aortic valve stenosis, insufficiency, or disorders, multiple involvement of mitral and aortic valves, mitral and aortic valve diseases, unspecified, diseases of tricuspid valve, tricuspid valve disorders, specified as nonrheumatic, pulmonary valve disorders, endocarditis, valve unspecified, endomyocardial fibrosis, endocardial fibroelastosis, other primary or secondary cardiomyopathies, cardiomyopathy, functional and undiagnosed cardiac murmurs, other abnormal heart sounds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Fibrosis Per 10,000 Participant-Years of Follow-Up</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Occurrence of: idiopathic retroperitoneal fibrosis, occlusion not otherwise specified (NOS) of ureter, diffuse (idiopathic) (interstitial) pulmonary fibrosis, Hamman-Rich syndrome, interstitial pneumonia (desquamative) (lymphoid), fibrosis of lung (atrophic; confluent; massive; perialveolar; peribronchial) chronic or unspecified, pulmonary or pleural fibrosis, abnormal communication between pericardial and pleural sacs, pleural fold anomaly, adhesive or constrictive pericarditis, pericardial fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Heart Failure Per 10,000 Participant-Years of Follow-Up</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Occurrence of: unspecified acute edema of lung, heart failure, acute pulmonary heart disease, or acute cor pulmonale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With All-Cause Mortality Per 10,000 Participant-Years of Follow-Up</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>All participants who died independent of the cause to include instantaneous death, death occurring in less than 24 hours from onset of symptoms, not otherwise explained, unattended death and other causes of ill defined morbidity and mortality. Cause of death was coded and classified as either cardiovascular or respiratory.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">86939</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Hyperprolactinemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>All persons who newly start one of the dopamine agonists (DA) after start of eligibility period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>All persons who started levodopa after start of eligibility period and had not been treated with dopamine agonists anytime prior.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>All persons with newly diagnosed hyperprolactinemia who had not been treated with dopamine agonists anytime prior.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <description>healthy controls from general population matched on age, gender, index date and general practitioner (GP) practice to persons exposed to dopamine agonists</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Retrospective study-</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Retrospective study-</intervention_name>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Retrospective study-</intervention_name>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Retrospective study-</intervention_name>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        General research practice databases or record linkage systems in Europe that provide access
        to original medical information. These are: The Health Information Network (THIN), Health
        Search Database (HSD)-THALES, the Integrated Primary Care Information (IPCI) and
        PHARMO-Record Linkage System (RLS) and meeting criteria for entry into any of the 4 cohorts
        between 1995 - 2007
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one year registered with the general practitioner (GP), one year of valid
             data from the GP, or the date of software conversion (if GP software systems had
             changed) and meeting criteria for any one of the 4 cohorts as defined.

        Exclusion Criteria:

          -  rheumatic heart disease

          -  congenital heart disease: includes structural defects, congenital arrhythmias, and
             cardiomyopathies

          -  dilated cardiomyopathy (congestive cardiomyopathy

          -  pericardial, pleural, pulmonary or retroperitoneal fibrosis

          -  endocarditis or myocarditis

          -  carcinoid syndrome

          -  intravenous drug abuse

          -  fibrotic valvular heart disease

          -  pleural/pulmonary/pericardial/retroperitoneal fibroses

          -  use of fenfluramine or amiodarone within 3 years prior to date of diagnosis of
             fibrotic valvular heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7231031&amp;StudyName=The%20Association%20between%20Dopamine%20Agonists%20and%20Cardiac%20Valvulopathy%2C%20Fibrosis%20and%20Other%20Cardiopulmonary%20Events</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <results_first_submitted>December 28, 2010</results_first_submitted>
  <results_first_submitted_qc>February 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2011</results_first_posted>
  <last_update_submitted>March 17, 2011</last_update_submitted>
  <last_update_submitted_qc>March 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>dopamine agonists</keyword>
  <keyword>cabergoline</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>hyperprolactinemia</keyword>
  <keyword>epidemiology</keyword>
  <keyword>cardiac valvulopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Hyperprolactinemia</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Noninterventional retrospective cohort study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dopamine Agonist (Cohort 1)</title>
          <description>Participants with Parkinson's Disease (PD)/Parkinsonism, Restless Legs Syndrome (RLS) or hyperprolactinemia (previously treated) who newly started one of the ergot-derived Dopamine Agonists (DAs): Lisuride, Cabergoline, Metergoline, Bromocriptine, Pergolide, Dihydroergocryptine mesylate, Quinagolide, Ropinirole, Pramipexole, Piribedil, or Rotigotine.</description>
        </group>
        <group group_id="P2">
          <title>Levodopa (Cohort 2)</title>
          <description>Participants with PD/Parkinsonism or RLS who newly started treatment with Levodopa: Levodopa and decarboxylase inhibitor; Levodopa, decarboxylase inhibitor and catechol-O-methyl transferase [COMT] inhibitor; MeLevodopa; MeLevodopa and decarboxylase inhibitor; or EtiLevodopa and decarboxylase inhibitor and had not been treated with DAs anytime prior.</description>
        </group>
        <group group_id="P3">
          <title>Hyperprolactinemia (Cohort 3)</title>
          <description>Participants with newly diagnosed hyperprolactinemia (excluding postpartum hyperprolactinemia), who had not been treated with DAs anytime prior.</description>
        </group>
        <group group_id="P4">
          <title>Healthy Controls (Cohort 4)</title>
          <description>Healthy control participants matched (1:1) with participants in the DA cohort (Cohort 1) for age (exact year), gender, database and date of start of DA.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27812"/>
                <participants group_id="P2" count="14669"/>
                <participants group_id="P3" count="15147"/>
                <participants group_id="P4" count="29311"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27812"/>
                <participants group_id="P2" count="14669"/>
                <participants group_id="P3" count="15147"/>
                <participants group_id="P4" count="29311"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dopamine Agonist (Cohort 1)</title>
          <description>Participants with Parkinson's Disease (PD)/Parkinsonism, Restless Legs Syndrome (RLS) or hyperprolactinemia (previously treated) who newly started one of the ergot-derived Dopamine Agonists (DAs): Lisuride, Cabergoline, Metergoline, Bromocriptine, Pergolide, Dihydroergocryptine mesylate, Quinagolide, Ropinirole, Pramipexole, Piribedil, or Rotigotine.</description>
        </group>
        <group group_id="B2">
          <title>Levodopa (Cohort 2)</title>
          <description>Participants with PD/Parkinsonism or RLS who newly started treatment with Levodopa: Levodopa and decarboxylase inhibitor; Levodopa, decarboxylase inhibitor and catechol-O-methyl transferase [COMT] inhibitor; MeLevodopa; MeLevodopa and decarboxylase inhibitor; or EtiLevodopa and decarboxylase inhibitor and had not been treated with DAs anytime prior.</description>
        </group>
        <group group_id="B3">
          <title>Hyperprolactinemia (Cohort 3)</title>
          <description>Participants with newly diagnosed hyperprolactinemia (excluding postpartum hyperprolactinemia), who had not been treated with DAs anytime prior.</description>
        </group>
        <group group_id="B4">
          <title>Healthy Controls (Cohort 4)</title>
          <description>Healthy control participants matched (1:1) with participants in the DA cohort (Cohort 1) for age (exact year), gender, database and date of start of DA.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27812"/>
            <count group_id="B2" value="14669"/>
            <count group_id="B3" value="15147"/>
            <count group_id="B4" value="29311"/>
            <count group_id="B5" value="86939"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" spread="20.1"/>
                    <measurement group_id="B2" value="76.8" spread="0.1"/>
                    <measurement group_id="B3" value="40.0" spread="0.1"/>
                    <measurement group_id="B4" value="49.4" spread="0.1"/>
                    <measurement group_id="B5" value="52.0" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22084"/>
                    <measurement group_id="B2" value="7666"/>
                    <measurement group_id="B3" value="13398"/>
                    <measurement group_id="B4" value="21992"/>
                    <measurement group_id="B5" value="65140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5728"/>
                    <measurement group_id="B2" value="7003"/>
                    <measurement group_id="B3" value="1749"/>
                    <measurement group_id="B4" value="7319"/>
                    <measurement group_id="B5" value="21799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Fibrotic Valvular Heart Disease Per 10,000 Participant-Years of Follow-Up</title>
        <description>Occurrence of: mitral stenosis with insufficiency, other unspecified mitral valve diseases, mitral or aortic valve stenosis, insufficiency, or disorders, multiple involvement of mitral and aortic valves, mitral and aortic valve diseases, unspecified, diseases of tricuspid valve, tricuspid valve disorders, specified as nonrheumatic, pulmonary valve disorders, endocarditis, valve unspecified, endomyocardial fibrosis, endocardial fibroelastosis, other primary or secondary cardiomyopathies, cardiomyopathy, functional and undiagnosed cardiac murmurs, other abnormal heart sounds.</description>
        <time_frame>Up to 12 years</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Dopamine Agonist (Cohort 1)</title>
            <description>Participants with Parkinson's Disease (PD)/Parkinsonism, Restless Legs Syndrome (RLS) or hyperprolactinemia (previously treated) who newly started one of the ergot-derived Dopamine Agonists (DAs): Lisuride, Cabergoline, Metergoline, Bromocriptine, Pergolide, Dihydroergocryptine mesylate, Quinagolide, Ropinirole, Pramipexole, Piribedil, or Rotigotine.</description>
          </group>
          <group group_id="O2">
            <title>Levodopa (Cohort 2)</title>
            <description>Participants with PD/Parkinsonism or RLS who newly started treatment with Levodopa: Levodopa and decarboxylase inhibitor; Levodopa, decarboxylase inhibitor and catechol-O-methyl transferase [COMT] inhibitor; MeLevodopa; MeLevodopa and decarboxylase inhibitor; or EtiLevodopa and decarboxylase inhibitor and had not been treated with DAs anytime prior.</description>
          </group>
          <group group_id="O3">
            <title>Hyperprolactinemia (Cohort 3)</title>
            <description>Participants with newly diagnosed hyperprolactinemia (excluding postpartum hyperprolactinemia), who had not been treated with DAs anytime prior.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls (Cohort 4)</title>
            <description>Healthy control participants matched (1:1) with participants in the DA cohort (Cohort 1) for age (exact year), gender, database and date of start of DA.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fibrotic Valvular Heart Disease Per 10,000 Participant-Years of Follow-Up</title>
          <description>Occurrence of: mitral stenosis with insufficiency, other unspecified mitral valve diseases, mitral or aortic valve stenosis, insufficiency, or disorders, multiple involvement of mitral and aortic valves, mitral and aortic valve diseases, unspecified, diseases of tricuspid valve, tricuspid valve disorders, specified as nonrheumatic, pulmonary valve disorders, endocarditis, valve unspecified, endomyocardial fibrosis, endocardial fibroelastosis, other primary or secondary cardiomyopathies, cardiomyopathy, functional and undiagnosed cardiac murmurs, other abnormal heart sounds.</description>
          <population>Per protocol.</population>
          <units>Participants/10,000 Participant-Years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27812"/>
                <count group_id="O2" value="14669"/>
                <count group_id="O3" value="15147"/>
                <count group_id="O4" value="29311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="NA">Due to limited number of exposed cases in hyperprolactinemia cohort, no additional analyses beyond exploration of cabergoline and other single products (current, past) vs non-use, and where possible, dose/duration effect could be performed.</measurement>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Fibrosis Per 10,000 Participant-Years of Follow-Up</title>
        <description>Occurrence of: idiopathic retroperitoneal fibrosis, occlusion not otherwise specified (NOS) of ureter, diffuse (idiopathic) (interstitial) pulmonary fibrosis, Hamman-Rich syndrome, interstitial pneumonia (desquamative) (lymphoid), fibrosis of lung (atrophic; confluent; massive; perialveolar; peribronchial) chronic or unspecified, pulmonary or pleural fibrosis, abnormal communication between pericardial and pleural sacs, pleural fold anomaly, adhesive or constrictive pericarditis, pericardial fibrosis</description>
        <time_frame>Up to 12 years</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Dopamine Agonist (Cohort 1)</title>
            <description>Participants with Parkinson's Disease (PD)/Parkinsonism, Restless Legs Syndrome (RLS) or hyperprolactinemia (previously treated) who newly started one of the ergot-derived Dopamine Agonists (DAs): Lisuride, Cabergoline, Metergoline, Bromocriptine, Pergolide, Dihydroergocryptine mesylate, Quinagolide, Ropinirole, Pramipexole, Piribedil, or Rotigotine.</description>
          </group>
          <group group_id="O2">
            <title>Levodopa (Cohort 2)</title>
            <description>Participants with PD/Parkinsonism or RLS who newly started treatment with Levodopa: Levodopa and decarboxylase inhibitor; Levodopa, decarboxylase inhibitor and catechol-O-methyl transferase [COMT] inhibitor; MeLevodopa; MeLevodopa and decarboxylase inhibitor; or EtiLevodopa and decarboxylase inhibitor and had not been treated with DAs anytime prior.</description>
          </group>
          <group group_id="O3">
            <title>Hyperprolactinemia (Cohort 3)</title>
            <description>Participants with newly diagnosed hyperprolactinemia (excluding postpartum hyperprolactinemia), who had not been treated with DAs anytime prior.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls (Cohort 4)</title>
            <description>Healthy control participants matched (1:1) with participants in the DA cohort (Cohort 1) for age (exact year), gender, database and date of start of DA.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fibrosis Per 10,000 Participant-Years of Follow-Up</title>
          <description>Occurrence of: idiopathic retroperitoneal fibrosis, occlusion not otherwise specified (NOS) of ureter, diffuse (idiopathic) (interstitial) pulmonary fibrosis, Hamman-Rich syndrome, interstitial pneumonia (desquamative) (lymphoid), fibrosis of lung (atrophic; confluent; massive; perialveolar; peribronchial) chronic or unspecified, pulmonary or pleural fibrosis, abnormal communication between pericardial and pleural sacs, pleural fold anomaly, adhesive or constrictive pericarditis, pericardial fibrosis</description>
          <population>Per protocol.</population>
          <units>Participants/10,000 Participant-Years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27812"/>
                <count group_id="O2" value="14669"/>
                <count group_id="O3" value="15147"/>
                <count group_id="O4" value="29311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="NA">Due to limited number of exposed cases in hyperprolactinemia cohort, no additional analyses beyond exploration of cabergoline and other single products (current, past) vs non-use, and where possible, dose/duration effect could be performed.</measurement>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Heart Failure Per 10,000 Participant-Years of Follow-Up</title>
        <description>Occurrence of: unspecified acute edema of lung, heart failure, acute pulmonary heart disease, or acute cor pulmonale</description>
        <time_frame>Up to 12 years</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Dopamine Agonist (Cohort 1)</title>
            <description>Participants with Parkinson's Disease (PD)/Parkinsonism, Restless Legs Syndrome (RLS) or hyperprolactinemia (previously treated) who newly started one of the ergot-derived Dopamine Agonists (DAs): Lisuride, Cabergoline, Metergoline, Bromocriptine, Pergolide, Dihydroergocryptine mesylate, Quinagolide, Ropinirole, Pramipexole, Piribedil, or Rotigotine.</description>
          </group>
          <group group_id="O2">
            <title>Levodopa (Cohort 2)</title>
            <description>Participants with PD/Parkinsonism or RLS who newly started treatment with Levodopa: Levodopa and decarboxylase inhibitor; Levodopa, decarboxylase inhibitor and catechol-O-methyl transferase [COMT] inhibitor; MeLevodopa; MeLevodopa and decarboxylase inhibitor; or EtiLevodopa and decarboxylase inhibitor and had not been treated with DAs anytime prior.</description>
          </group>
          <group group_id="O3">
            <title>Hyperprolactinemia (Cohort 3)</title>
            <description>Participants with newly diagnosed hyperprolactinemia (excluding postpartum hyperprolactinemia), who had not been treated with DAs anytime prior.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls (Cohort 4)</title>
            <description>Healthy control participants matched (1:1) with participants in the DA cohort (Cohort 1) for age (exact year), gender, database and date of start of DA.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Heart Failure Per 10,000 Participant-Years of Follow-Up</title>
          <description>Occurrence of: unspecified acute edema of lung, heart failure, acute pulmonary heart disease, or acute cor pulmonale</description>
          <population>Per protocol.</population>
          <units>Participants/10,000 Participant-Years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27812"/>
                <count group_id="O2" value="14669"/>
                <count group_id="O3" value="15147"/>
                <count group_id="O4" value="29311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="161"/>
                    <measurement group_id="O3" value="NA">Due to limited number of exposed cases in hyperprolactinemia cohort, no additional analyses beyond exploration of cabergoline and other single products (current, past) vs non-use, and where possible, dose/duration effect could be performed.</measurement>
                    <measurement group_id="O4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With All-Cause Mortality Per 10,000 Participant-Years of Follow-Up</title>
        <description>All participants who died independent of the cause to include instantaneous death, death occurring in less than 24 hours from onset of symptoms, not otherwise explained, unattended death and other causes of ill defined morbidity and mortality. Cause of death was coded and classified as either cardiovascular or respiratory.</description>
        <time_frame>Up to 12 years</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Dopamine Agonist (Cohort 1)</title>
            <description>Participants with Parkinson's Disease (PD)/Parkinsonism, Restless Legs Syndrome (RLS) or hyperprolactinemia (previously treated) who newly started one of the ergot-derived Dopamine Agonists (DAs): Lisuride, Cabergoline, Metergoline, Bromocriptine, Pergolide, Dihydroergocryptine mesylate, Quinagolide, Ropinirole, Pramipexole, Piribedil, or Rotigotine.</description>
          </group>
          <group group_id="O2">
            <title>Levodopa (Cohort 2)</title>
            <description>Participants with PD/Parkinsonism or RLS who newly started treatment with Levodopa: Levodopa and decarboxylase inhibitor; Levodopa, decarboxylase inhibitor and catechol-O-methyl transferase [COMT] inhibitor; MeLevodopa; MeLevodopa and decarboxylase inhibitor; or EtiLevodopa and decarboxylase inhibitor and had not been treated with DAs anytime prior.</description>
          </group>
          <group group_id="O3">
            <title>Hyperprolactinemia (Cohort 3)</title>
            <description>Participants with newly diagnosed hyperprolactinemia (excluding postpartum hyperprolactinemia), who had not been treated with DAs anytime prior.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls (Cohort 4)</title>
            <description>Healthy control participants matched (1:1) with participants in the DA cohort (Cohort 1) for age (exact year), gender, database and date of start of DA.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-Cause Mortality Per 10,000 Participant-Years of Follow-Up</title>
          <description>All participants who died independent of the cause to include instantaneous death, death occurring in less than 24 hours from onset of symptoms, not otherwise explained, unattended death and other causes of ill defined morbidity and mortality. Cause of death was coded and classified as either cardiovascular or respiratory.</description>
          <population>Per protocol.</population>
          <units>Participants/10,000 Participant-Years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27812"/>
                <count group_id="O2" value="14669"/>
                <count group_id="O3" value="15147"/>
                <count group_id="O4" value="29311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="803"/>
                    <measurement group_id="O3" value="NA">Due to limited number of exposed cases in hyperprolactinemia cohort, no additional analyses beyond exploration of cabergoline and other single products (current, past) vs non-use, and where possible, dose/duration effect could be performed.</measurement>
                    <measurement group_id="O4" value="719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Information about adverse events was not collected during this observational, noninterventional, case control study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dopamine Agonist (Cohort 1)</title>
          <description>Participants with Parkinson's Disease (PD)/Parkinsonism, Restless Legs Syndrome (RLS) or hyperprolactinemia (previously treated) who newly started one of the ergot-derived Dopamine Agonists (DAs): Lisuride, Cabergoline, Metergoline, Bromocriptine, Pergolide, Dihydroergocryptine mesylate, Quinagolide, Ropinirole, Pramipexole, Piribedil, or Rotigotine.</description>
        </group>
        <group group_id="E2">
          <title>Levodopa (Cohort 2)</title>
          <description>Participants with PD/Parkinsonism or RLS who newly started treatment with Levodopa: Levodopa and decarboxylase inhibitor; Levodopa, decarboxylase inhibitor and catechol-O-methyl transferase [COMT] inhibitor; MeLevodopa; MeLevodopa and decarboxylase inhibitor; or EtiLevodopa and decarboxylase inhibitor and had not been treated with DAs anytime prior.</description>
        </group>
        <group group_id="E3">
          <title>Hyperprolactinemia (Cohort 3)</title>
          <description>Participants with newly diagnosed hyperprolactinemia (excluding postpartum hyperprolactinemia), who had not been treated with DAs anytime prior.</description>
        </group>
        <group group_id="E4">
          <title>Healthy Controls (Cohort 4)</title>
          <description>Healthy control participants matched (1:1) with participants in the DA cohort (Cohort 1) for age (exact year), gender, database and date of start of DA.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

